Stimulant Treatment for ADHD During Pregnancy
Lisdexamfetamine (Vyvanse) is a central nervous system stimulant that is generally considered to have reassuring reproductive safety data when used as prescribed for ADHD, with clinical decisions based on balancing maternal functional benefits against potential pregnancy risks. [1] Available pregnancy data for amphetamine-class stimulant exposure (including lisdexamfetamine, which is converted to dextroamphetamine) have not shown a consistent increase in miscarriage or birth defects, but mixed evidence exists for outcomes such as preterm delivery and hypertensive disorders. [2]
Medication Selection Algorithm
Stimulant therapy for ADHD in pregnancy is selected using individualized risk–benefit assessment. [1] When stimulant treatment is used, selection is typically limited to prescribed, therapeutic dosing. [1] Lisdexamfetamine is an amphetamine-class stimulant that is metabolized in the body to dextroamphetamine. [2]
Key Evidence Supporting This Recommendation
Prescribed dextroamphetamine exposure in pregnancy has not been associated with a consistent increase in miscarriage risk across studies. [2] Studies have not reported an increased chance of birth defects with prescribed dextroamphetamine exposure. [2] In one study of more than 500 women who continued dextroamphetamine throughout pregnancy, threatened miscarriage was lower compared with stopping medication. [2] For pregnancy complications, a study of over 500 women found no significant increase in low birth weight or preterm delivery when compared with women with ADHD who stopped medication. [2] Larger studies of prescribed amphetamines have shown mixed results for preterm delivery and for high blood pressure and preeclampsia. [2] Higher exposure intensity (higher doses, more frequent dosing, or nonprescribed use) has been associated with increased risks of poor fetal growth, low birth weight, and preterm delivery. [2]
Monotherapy vs Combination Therapy
No guideline-directed ADHD regimen for pregnancy supports routine combination stimulant therapy. [1] When pharmacotherapy is used for moderate to severe ADHD symptoms, treatment is individualized, including consideration of stimulant pharmacotherapy when symptoms are not adequately managed with nonpharmacologic strategies. [1]
Important Clarifications and Nuances
Discontinuation decisions should be individualized and should avoid abrupt stopping without clinical oversight because stimulant withdrawal can occur after prolonged use. [2] Maternal baseline risk factors (including ADHD-related factors and comorbid conditions) can confound observed pregnancy outcomes in studies of stimulants. [2] Product labeling for lisdexamfetamine includes warnings that the medication may harm the unborn baby and advises prenatal monitoring considerations through the prescribing clinician. [3]
Initiation Thresholds and Indications
Pharmacotherapy for ADHD in the perinatal period is considered particularly for individuals with moderate or severe ADHD symptoms after individualized treatment planning. [1] Nonpharmacologic interventions (psychoeducation, self-management strategies, and psychotherapies) are recommended components of individualized treatment planning. [1]
Common Pitfalls to Avoid
Using amphetamine stimulants at higher doses than prescribed or more often than prescribed increases the risk of poor fetal growth, low birth weight, and preterm delivery. [2] Using stimulants without a prescription increases pregnancy risk. [2] Abrupt stopping after prolonged use can cause withdrawal; withdrawal effects on pregnancy are not known. [2]
Target Outcomes of Therapy
The primary treatment goal is symptom control sufficient to mitigate functional impairment during pregnancy through a risk–benefit–balanced plan. [1] If lisdexamfetamine is continued, blood pressure and heart rate monitoring during treatment is recommended by the prescribing information. [3]
Sources
[1] AJOG (2024): Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. [2] MotherToBaby (March 1, 2026): Dextroamphetamine fact sheet in pregnancy (used to infer lisdexamfetamine risk because lisdexamfetamine converts to dextroamphetamine). [3] DailyMed/FDA label (revised 09/2025): Lisdexamfetamine dimesylate capsules prescribing information.